
OUR ONCOLOGY TRIALS
Improving care for patients with advanced cancer

MULTIPLE SOLID TUMOUR TYPES
Immunotherapy
Masked anti-CTLA-4
ADG126-1001
First-in-Human, Open-Label, Phase I Dose Escalation Study of ADG126 in Patients with Advanced Malignancies
PHASE
I
STATUS
Active, Recruitment Closed
Personalised Cancer Vaccine
Neoantigen mRNA vaccine
SWP1001-06
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients with Advanced Malignant Solid Tumours
PHASE
I
STATUS
Closed to Recruitment
Immunotherapy combination
anti-PD-1 plus anti-CCR8
LM108-01-101
A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours
PHASE
I/II
STATUS
Recruiting
Immunotherapy
bispecific antibody directed against PD-L1 and CD47
BAT-7104-002-CR
A Phase I, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours
PHASE
I
STATUS
Recruiting
Immunotherapy combination
small molecule CD73 inhibitor plus anti-PD1
ATG-037-001 | STAMINA
A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
PHASE
I
STATUS
Recruiting
Targeted therapy combination
small molecule SHP2 inhibitor plus anti-PD-L1
GO43712
A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination with Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumours
PHASE
I
STATUS
Recruiting
Targeted therapy
small molecule EGFR/HER2 inhibitor
ORIC-114-01
An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
PHASE
I
STATUS
Recruiting
Targeted therapy
mRNA +/- anti-PD-L1
mRNA-2752-P101
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
PHASE
I
STATUS
Recruiting
Targeted therapy
mRNA +/- anti-PD-1
mRNA-4359-P101
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
PHASE
I
STATUS
Recruiting
Targeted therapy combination
SHP2i plus KRAS G12Ci
NAV-1003 (ARGONAUT)
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
PHASE
I
STATUS
Recruiting
Immunotherapy
ROR1 BiTE
EMB07X101
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors
PHASE
I
STATUS
Recruiting
Targeted therapy combination
HPKi +/- anti-PD-1 antibody
BGB-A317-15025-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
PHASE
I
STATUS
Coming Soon
Immunotherapy combination
anti-PD-1 + anti-LAG-3 + anti-TIM-3
INCAGN 2385-201
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
PHASE
I/II
STATUS
Coming Soon
Immunoconjugate
FRα antibody drug conjugate
AMT-151-01
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
PHASE
I
STATUS
Recruiting
Immunoconjugate combinations
IL-2 / anti-IL-2 conjugate +/- chemotherapy or ICI
SLC-3010-001
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors
PHASE
I
STATUS
Coming Soon

MELANOMA
Personalised Cancer Vaccine
patient-specific cancer neoepitope immunotherapy
EVX-01-001
An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination with Pembrolizumab in Checkpoint Inhibitor Treatment Naive Adults with Unresectable or Metastatic Melanoma
PHASE
II
STATUS
Active, Recruitment Closed
Targeted Adjuvant Therapy
BRAF/MEKi
COLUMBUS-AD
Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group.
PHASE
III
STATUS
Coming Soon
Adjuvant Immunotherapy
anti-PD-1 +/- anti-TIGIT
KEYVIBE-010
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled
Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus
Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma
PHASE
III
STATUS
Recruiting
Immunotherapy
anti-PD-1/LAG3 bispecific antibody
BP43963
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
PHASE
II
STATUS
Active, Recruitment Closed
Targeted Therapy combination
ATR Kinase inhibitor +/- anti-PD-L1 antibody
MONETTE
A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
PHASE
II
STATUS
Recruiting

LUNG CANCERS
Targeted therapy
ALK/ROS/RET targeted therapy vs immunotherapy
B042777
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
PHASE
I-III
STATUS
Recruiting
Immunotherapy combinations
anti-PD-1 +/- novel IO +/- chemotherapy
BGB-LC-201
A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
PHASE
II
STATUS
Recruiting

GASTROINTESTINAL CANCERS
Immunoconjugate
Antibody-drug conjugate
SHR-A1904-I-104
An Open-label, Single-arm, Multi-center Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1904 in Subjects with Advanced Solid Tumours
PHASE
I-IIa
STATUS
Recruiting
Immunotherapy combinations
chemotherapy combination +/- anti-PD-1 +/- anti-LAG-3
BGB-A317-LBL-007-201
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer